Table 2. Putative cerebrospinal fluid (CSF) autoantibody biomarkers of Alzheimer’s disease (AD), selected based on 1) identification in half or more of the patient group and 2) present in one or less individuals of the control group.
| Control individuals | AD group | PD group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein name | Number of
individuals identified |
Total
unique peptides |
Mean
unique peptides |
Number
of patients identified |
Total
unique peptides |
Mean
unique peptides |
Number
of patients identified |
Total
unique peptides |
Mean
unique peptides |
| Glia-derived nexin
(SERPINE2) |
0 | 0 | 0 | 8 | 7 | 2.3 | 3 | 2 | 1 |
| Fibromodulin
(FMOD) |
0 | 0 | 0 | 6 | 4 | 1.5 | 0 | 0 | 0 |
| Quinone
oxidoreductase (NQO1) |
0 | 0 | 0 | 5 | 1 | 1 | 3 | 1 | 1 |
| Cathepsin F (CTSF) | 1 | 1 | 1 | 6 | 5 | 2.3 | 1 | 1 | 1 |
| Cadherin-13
(CDH13) |
1 | 1 | 1 | 6 | 5 | 2 | 1 | 1 | 1 |
| Phospholipase D4
(PLD4) |
1 | 1 | 1 | 6 | 1 | 1 | 3 | 1 | 1 |
| Inositol 1,4,5-
triphosphate receptor type 1 (ITPR1) |
1 | 1 | 1 | 5 | 6 | 1.4 | 0 | 0 | 0 |
| Sushi repeat-
containing protein (SRPX) |
1 | 1 | 1 | 5 | 5 | 1.8 | 3 | 1 | 1 |
| Sarco/endoplasmic
reticulum calcium ATPase 2 (ATP2A2) |
1 | 1 | 1 | 5 | 5 | 1.2 | 2 | 1 | 1 |
| Oligodendrocyte-
myelin glycoprotein (OMG) |
1 | 1 | 1 | 5 | 4 | 1.4 | 3 | 1 | 1 |
| 4F2 cell-surface
antigen heavy chain (SLC3A2) |
1 | 1 | 1 | 5 | 4 | 1.2 | 2 | 1 | 1 |
| WD repeat-
containing protein 1 (WDR1) |
1 | 1 | 1 | 5 | 3 | 1.4 | 2 | 2 | 1.5 |
| Isoaspartyl
peptidase (ASRGL1) |
1 | 1 | 1 | 5 | 2 | 1.4 | 2 | 1 | 1 |
| Heterogeneous
nuclear ribonucleoprotein H (hnRNP H) |
1 | 1 | 1 | 5 | 2 | 1.2 | 1 | 1 | 1 |
| Metalloproteinase
inhibitor 2 (TIMP-2) |
1 | 1 | 1 | 5 | 2 | 1.2 | 1 | 1 | 1 |
| Cerebellin-3
(CBLN3) |
1 | 1 | 1 | 5 | 2 | 1 | 0 | 0 | 0 |